STOCKSCOUTER

StockScouter Premium

StockScouter Screener and Portfolios are now in our premium offering.
Learn more or Get it now! Stockscouter Portfolio performance

ABUS ARBUTUS BIOPHARMA CORPORATION StockScouter® Report

2

StockScouter® Score

ARBUTUS BIOPHARMA CORPORATION, a micro cap growth company in the healthcare sector, is expected to underperform the market over the next six months with higher than average risk

10 is the best possible rating. Learn more.

Summary

Positives

  • The enterprise value-to-sales ratio is much lower than the average for comparably-sized companies in the StockScouter universe. Very Positive

 

Concerns

  • The most recent quarterly earnings report was significantly lower than analysts’ consensus forecast. Negative
  • One or more analysts has significantly decreased quarterly earnings estimates for ABUS. Negative
  • Earnings growth in the past year has decelerated rapidly compared to earnings growth in the past three years. Negative

 

Short-term Outlook

Over the next 1-2 months, StockScouter forecasts that micro cap stocks will be neutral, growth stocks will be in favor, and healthcare stocks will be neutral.

Expected Risk/Return

Progress: 100% done.
Progress: 20% done.
Low
High

Core Model Grades

F
C
A
F

Previous Ratings

2
3
2